Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 16/20 | 0.65 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31675943 | 0.86 | SPPL2A (0.79) | SPPL2AXIAPPSEN1PSEN2APH1B | |
| SCHEMBL25406336 | 0.82 | SPPL2A (0.69) | SPPL2AXIAPPSEN1PSEN2APH1B | |
| SCHEMBL25406333 | 0.82 | SPPL2A (0.69) | SPPL2AXIAPPSEN1PSEN2APH1B | |
| SCHEMBL30617041 | 0.81 | SPPL2A (0.80) | SPPL2AXIAPPSEN1PSEN2APH1B | |
| SCHEMBL26853936 | 0.80 | SPPL2A (0.70) | SPPL2AXIAPPSEN1PSEN2APH1B | |
| SCHEMBL26853473 | 0.80 | SPPL2A (0.79) | SPPL2AXIAPPSEN1PSEN2APH1B | |
| SCHEMBL26848152 | 0.80 | SPPL2A (0.78) | SPPL2AXIAP | |
| SCHEMBL25409267 | 0.79 | SPPL2A (0.64) | SPPL2AXIAPPSEN1PSEN2APH1B | |
| SCHEMBL25409264 | 0.79 | SPPL2A (0.64) | SPPL2AXIAPPSEN1PSEN2APH1B | |
| SCHEMBL26848163 | 0.79 | SPPL2A (0.77) | SPPL2AXIAPPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263416-A1 | SPPL2a INHIBITORS | INCYTE CORPORATION | 2025-08-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263416-A1 | SPPL2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | SPPL2A 1/4885NAMPT 2018/4885XIAP 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.